| 120 | 4 | 4 |
| 下载次数 | 被引频次 | 阅读次数 |
目的对照性分析非酒精性脂肪性肝病(NAFLD)临床特点,探讨海狗油ω-3多不饱和脂肪酸胶丸(海狗油)对NAFLD的治疗效果。方法①收集NAFLD患者和正常健康人资料各76例,以病例对照研究方法分析NAFLD的临床生化指标。②选取18例NAFLD患者,予以海狗油连续治疗12周,动态观察海狗油对NAFLD患者临床生化和影像学检查结果的影响。结果①NAFLD组体重指数(BMI)、谷丙转氨酶(ALT)、甘油三酯(TG)、极低密度脂蛋白胆固醇(VLDL-C)、空腹血糖(FPG)显著高于对照组(P<0.01),两组间AST和TCH差异无显著性。②NAFLD组合并肥胖、高血压、血脂紊乱、高血糖中两项或两项以上者和代谢综合征者分别为72.37%(55/76)和46.05%(35/76)。③与治疗前比较,海狗油治疗4周末和8周末时,NAFLD患者的血清LP-a显著降低(P<0.01);治疗12周末时,血清Apo-A1明显降低(P<0.05),肝/脾CT值比值的差异无显著性(P>0.05)。结论NAFLD与肥胖、血脂紊乱和高血糖密切相关,海狗油对NAFLD患者的血脂有一定调节作用。
Abstract：Objective To investigate the clinical characters of nonalcoholic fatty liver disease (NAFLD)and observe the effect of seal oil ω-3 polyunsaturated fatty acid (seal oil) on patients with NAFLD. Methods ① 76 patients with NAFLD and 76 health people were enrolled, the clinical characters of NAFLD were analyzed by case control study. ② 18 patients selected from above-mentioned 76 patients with NAFLD were treated by sea oil consecutively for 12 weeks, clinical biochemistry indexes and imaging results were obseverd dynamicly.Results ① The BMI, ALT, TG, VLDL-C and FPG of NAFLD patients was significantly higher than that of control group respectively(P<0.01), there were no significant difference in AST and TCH between two groups. ② Patients in NAFLD group complicated with two and more than two of obesity, hypertension, dyslipidemia, hyperglycaemia and metabolic syndrome was 72.37%(55/76) and 46.05%(35/76), respectively. ③ Serum LP-a was decreased significantly after treated by sea oil for 4 weeks and 8 weeks(P<0.01). After 12 weeks treatment serum Apo-A1 was decreased significantly(P<0.05), the difference in liver-to-spleen attenuation ratio between pretherapy and post-treatment wasn′t significant(P>0.05).Conclusion NAFLD is closely correlated with obesity, dyslipidemia and hyperglycaemia, seal oil exerts regulation effects against the dyslipidemia of the NAFLD patients.
[1]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊断标准[J].中华肝脏病杂志,2003,11(2):71.
[2]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-61.
[3]Angulo P.Nonalcoholic fatty liver disease[J].N Engl J Med,2002,346(16):1221-31.
[4]Reid A E.Nonalcoholic steatohepatitis[J].Gastroenterology,2001,121(3):710-23.
[5]Marchesini G,Marzocchi R,Agostini F,et al.Nonalcoholic fatty liver disease and the metabolic syndrome[J].Curr Opin Lipidol,2005,16(4):421-7.
[6]Sekiya M,Yahagi N,Matsuzaka T,et al.Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1suppression[J].Hepatology,2003,38(6):1529-39.
[7]Levy J R,Clore J N,Stevens W.Dietary n-3polyunsaturated fatty acids decrease hepatic triglycerides in Fischer344rats[J].Hepa-tology,2004,39(3):608-16.
[8]Capanni M,Calella F,Biagini MR,et al.Prolonged n-3polyunsat-urated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a pilot study[J].Aliment Pharmacol Ther,2006,23(8):1143-51.
[9]Oliva MR,Mortele KJ,Segatto E,et al.Computed tomography fea-tures of nonalcoholic steatohepatitis with histopathologic correlation[J].J Comput Assist Tomogr,2006,30(1):37-43.
基本信息:
DOI：10.19405/j.cnki.issn1000-1492.2007.02.030
中图分类号:R575.5
引用信息:
[1]朱振,宋育林,胡乃中等.非酒精性脂肪性肝病临床分析及海狗油疗效观察[J].安徽医科大学学报,2007(02):221-224.DOI:10.19405/j.cnki.issn1000-1492.2007.02.030.
基金信息: